Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $4.94 Consensus PT from Brokerages
Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) have earned an average rating of “Hold” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy […]
Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) have earned an average rating of “Hold” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy […]
